Two compounds boost the ability of melanoma cells to invade other tissues in mice, providing additional evidence that antioxidants can be beneficial to malignant cells as well as healthy ones
MRV Research
CTLA-4 therapy yields durable responses in some patients with advanced melanoma
Tremelimumab conferred durable objective responses that lasted 12 years or more in patients with advanced melanoma, according to results of a retrospective, multi-institutional study.
Exelixis Announces Positive Overall Survival Results from Phase 3 Pivotal Trial of Cobimetinib in Combination with Vemurafenib in Patients with BRAF V600 Mutation-Positive Advanced Melanoma
Exelixis, Inc. today announced positive overall survival (OS) results from coBRIM, the phase 3 pivotal trial evaluating cobimetinib, a specific MEK inhibitor discovered by Exelixis, in combination with vemurafenib in previously untreated patients with unresectable locally advanced or metastatic melanoma carrying a BRAF V600 mutation. Exelixis’ collaborator Genentech, a member of the Roche Group, informed the company that coBRIM met its secondary endpoint of demonstrating a statistically significant and clinically meaningful increase in overall survival for patients receiving the combination of cobimetinib and vemurafenib, as compared to vemurafenib monotherapy. Ongoing study monitoring did not identify any new safety signals. Long-term safety data are expected later this year. These data will be the subject of a presentation at an upcoming medical meeting.
Cobimetinib/Vemurafenib Combo Improves Survival in Melanoma – See more at
The combination of the BRAF inhibitor vemurafenib and the MEK inhibitor cobimetinib demonstrated a statistically significant improvement in overall survival (OS) compared with vemurafenib alone for previously untreated patients with BRAFV600-mutant unresectable or metastatic melanoma, according to new findings from the coBRIM study.